# Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

> **NCT04323956** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 50 (actual)

## Conditions studied

- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage II Follicular Lymphoma
- Ann Arbor Stage II Marginal Zone Lymphoma
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage III Follicular Lymphoma
- Ann Arbor Stage III Marginal Zone Lymphoma
- Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage IV Follicular Lymphoma
- Ann Arbor Stage IV Marginal Zone Lymphoma
- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Indolent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Parsaclisib
- **BIOLOGICAL:** Pegfilgrastim
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT04323956
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-15
- **Primary completion:** 2023-10-04
- **Final completion:** 2028-05-16
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323956, "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04323956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*